2022
DOI: 10.1016/j.gim.2022.01.237
|View full text |Cite
|
Sign up to set email alerts
|

eP201: A phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec for treating patients with Duchenne muscular dystrophy

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles